Therefore, regulating the abnormal expression of SOD1 mutant protein or increasing its degradation rate has become the goal of many therapeutic ALS studies (van Zundert and Brown, 2017; Bravo-Hernandez et al., 2020; Duan et al., 2020). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.